Conference
LBA7_PR NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Authors
Socinski M; Creelan B; Horn L; Reck M; Paz-Ares L; Steins M; Felip E; van den Heuvel M; Ciuleanu TE; Badin F
Volume
27
Publisher
Elsevier
Publication Date
October 1, 2016
DOI
10.1093/annonc/mdw435.39
Conference proceedings
Annals of Oncology
ISSN
0923-7534